Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT04128696 |
Title | Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3) |
Acronym | INDUCE-3 |
Recruitment | Terminated |
Gender | both |
Phase | Phase III |
Variant Requirements | No |
Sponsors | GlaxoSmithKline |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA | ROU | POL | NOR | NLD | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BRA | AUS | ARG |